More than three hundred King & Spalding lawyers across our litigation, transactional and regulatory teams devote all or a substantial portion of their practice to serving clients in every segment of the Life Sciences and Healthcare sectors.
The comprehensive scope of the practice is unique: from helping to establish the start-ups developing the latest breakthrough drugs and medical devices, to defending the world’s largest pharmaceutical manufacturers in precedent-setting legal challenges, to representing major healthcare systems on their thorniest Medicare/Medicaid litigation or their strategic acquisitions, to counseling on the full spectrum of regulatory matters that these diverse entities face. We fully leverage our ability to draw on our broad experience as we work together to achieve outcomes that best protect and advance the interests of our clients across these sectors.
The lawyers in this group bring exceptionally deep industry and technical knowledge, many with advanced degrees in life sciences and medical fields as well as professional experience as scientists, surgeons, engineers, in-house lawyers and executives, senior regulators at the FDA, HHS and CMS, and enforcement officials at the DOJ.
Named Law 360s Life Sciences Firm of the Year for 2016, the firm currently represents more than 200 pharmaceutical, biotechnology and medical device manufacturers overall, including eight of the top 10 pharmaceutical/biotechnology manufacturers and eight of the top 10 medical device manufacturers. We offer clients our unique perspective at every stage of the product life cycle — from emerging growth company counseling on intellectual property, capital-raising transactions, license and corporate partnering agreements, and clinical trials, through FDA approval, manufacturing, marketing, commercial and post-approval regulatory, strategic M&A, and other corporate transactions, to litigation and government and internal investigation matters. Our government affairs lawyers also help our clients in the industry understand and navigate legislative and regulatory developments in Washington, D.C., and in state capitals across the country.
The firm has one of the U.S.’s largest practices representing organizations involved in the delivery of healthcare services and products across all facets of the legal issues they face. We serve the entire spectrum of healthcare institutional providers, practitioners, payors, educators, researchers, inventors, suppliers, investors and manufacturers across the nation.
Matthew’s practice focuses on representing lenders, bondholders and companies in connection with restructuring matters, as well as a particular emphasis on distressed debt and insolvency issues.Read More
January 16, 2020
Congress Holds Hearing on Current & Future Federal Cannabis Policies
January 13, 2020
Health Headlines – January 13, 2020
January 7, 2020
FDA Issues Proposed Rule and Draft Guidance on Drug Importation
LMG Life Sciences
November 12, 2019
Law360 Recognizes Four King & Spalding Partners as 2019 MVPs